Pilot Randomized Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Depression in Patients with Non-Metastatic Breast Cancer (Depression)
Tele-IPT vs. Tele-Pharmacotherapy for Depression in Patients with Non-Metastatic Breast Cancer
Sponsor: Columbia University Velocity Grant
Enrolling: Male and Female Patients
Study Length: 12 Weeks
IRB Number: 8209
U.S. Govt. ID: NCT04973930
Contact: Alexandra Mackay: 646-774-8027 / alexandra.mackay@nyspi.columbia.edu
Additional Study Information: The goal of this research study is to compare evidence-based tele-therapies for patients with non-metastatic breast cancer and comorbid major depression. Participants will be randomly assigned (like by the flip of a coin) to receive twelve weeks of either interpersonal therapy (IPT) or pharmacotherapy with a serotonin reuptake inhibitor, either venlafaxine XR (Effexor) or escitalopram (Lexapro). All sessions will be held virtually via Zoom. Participants will be assessed by independent evaluators and will complete self-report questionnaires throughout the study. There will be a blood sample collected at the beginning and end of the study to measure C-reactive protein, a marker of inflammation elevated in both breast cancer and depression. Participants will be offered $50 compensation as a token of thanks for completing the final evaluation at Week 12.
John Markowitz, MD
Do You Qualify?
Are you currently depressed? Yes No
Have you been diagnosed with non-metastatic breast cancer in the last 10 years? Yes No
Do you have access to a smart phone, tablet, or computer with a camera and reliable internet connection? Yes No
Are you currently receiving treatment for depression? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Alexandra Mackay